Process teams published methods that could sharpen mRNA vaccine and therapeutic manufacturing: Sartorius and collaborators demonstrated rapid pH‑driven denaturation of dsRNA impurities at pH ≤3.5 to reduce dsRNA below 0.1% while preserving mRNA integrity and boosting downstream yields. The approach offers an aqueous, scalable alternative to cellulose or solvent‑heavy purification methods. Separately, Merck researchers advanced in‑line permittivity monitoring using Cole–Cole model parameters (critical frequency and delta‑epsilon) to detect apoptosis and stress responses in CHO cultures before traditional viability readouts. Together, these process innovations promise earlier detection of production failures and higher recovered yields — critical levers for mRNA and biologics scale‑up and cost control.